share_log

CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Kulkarni Samarth

CRISPR Therapeutics | 4：持股變動聲明-高管 Kulkarni Samarth

美股sec公告 ·  02/01 06:49
牛牛AI助理已提取核心訊息
CRISPR Therapeutics AG's CEO, Samarth Kulkarni, completed a stock transaction involving the sale of 50,000 common shares on January 29, 2024. The shares were sold at prices ranging from $60.5031 to $61.0998, resulting in a total market value of $3,025,572.69. Prior to this sale, Kulkarni exercised options to acquire the same number of shares at a price of $19.12 per share. Following the transactions, Kulkarni directly holds 187,377 common shares. Additionally, Kulkarni has an indirect beneficial ownership of 200,000 shares through The Kulkarni 2023 GRAT.
CRISPR Therapeutics AG's CEO, Samarth Kulkarni, completed a stock transaction involving the sale of 50,000 common shares on January 29, 2024. The shares were sold at prices ranging from $60.5031 to $61.0998, resulting in a total market value of $3,025,572.69. Prior to this sale, Kulkarni exercised options to acquire the same number of shares at a price of $19.12 per share. Following the transactions, Kulkarni directly holds 187,377 common shares. Additionally, Kulkarni has an indirect beneficial ownership of 200,000 shares through The Kulkarni 2023 GRAT.
CRISPR Therapeutics AG的首席執行官薩瑪斯·庫爾卡尼於2024年1月29日完成了一項涉及出售50,000股普通股的股票交易。這些股票的出售價格從60.5031美元到61.0998美元不等，總市值爲3,025,572.69美元。在此次出售之前，庫爾卡尼行使了期權，以每股19.12美元的價格收購了相同數量的股票。交易完成後，庫爾卡尼直接持有187,377股普通股。此外，庫爾卡尼通過庫爾卡尼2023年GRAT擁有20萬股股票的間接實益所有權。
CRISPR Therapeutics AG的首席執行官薩瑪斯·庫爾卡尼於2024年1月29日完成了一項涉及出售50,000股普通股的股票交易。這些股票的出售價格從60.5031美元到61.0998美元不等，總市值爲3,025,572.69美元。在此次出售之前，庫爾卡尼行使了期權，以每股19.12美元的價格收購了相同數量的股票。交易完成後，庫爾卡尼直接持有187,377股普通股。此外，庫爾卡尼通過庫爾卡尼2023年GRAT擁有20萬股股票的間接實益所有權。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。